Haemonetics stock performance snapshot after recent weakness Haemonetics (HAE) has drawn investor attention after a period of share price weakness, with the stock down about 9% over the past month and ...

Haemonetics beats Q4 EPS and revenue estimates, shares rise 1.4%, but gross margin falls 120 basis points as the company sets ...

Investors in Haemonetics Corporation HAE need to pay close attention to the stock based on moves in the options market lately. That is because the June 18, 2026 $40.00 Call had some of the highest ...

Haemonetics (HAE) came out with quarterly earnings of $1.29 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $1.24 per share a year ago. These figures ...

BOSTON, Jan. 14, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, ...

Q4 FY26 earnings call recap: revenue/EPS, FY27 guidance, Persona PLUS momentum, IVT inflection, and tariff risks—read now.

The most recent analyst rating on (HAE) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Haemonetics stock, see the HAE Stock Forecast page. According to Spark, ...

Haemonetics, which concentrates on hematology products and services, booked revenue of $327 million for the quarter. Although that was 5% down year over year, it handily topped the average analyst ...

Haemonetics (NYSE:HAE) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table ...

Haemonetics Corporation HAE is progressing well with its growth strategies like the expansion of the product portfolio within its plasma and Hemostasis Management franchise. However, economic ...